Enlivex Announces Dosing Of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra In Patients With Sepsis
Portfolio Pulse from Happy Mohamed
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) has announced the dosing of the first patient under the amended protocol for its Phase II trial of Allocetra in patients with sepsis. The amended protocol allows for a higher SOFA score inclusion range, enabling the recruitment of patients with higher levels of sepsis severity. The company expects the top-line data readout from the Phase II trial in Q1 2024.
July 31, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enlivex's announcement of the first patient dosing under the amended protocol for its Phase II trial of Allocetra could potentially boost investor confidence in the company's clinical progress.
The announcement of the first patient dosing under the amended protocol for Enlivex's Phase II trial of Allocetra indicates progress in the company's clinical trials. This could potentially boost investor confidence in the company's ability to execute its clinical development plans, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100